How to Get Vyleesi (Bremelanotide) in Colorado

What Is Vyleesi and Why Does It Require a Prescription?

Bremelanotide, sold as Vyleesi, is a subcutaneous melanocortin receptor agonist that the FDA approved on June 21, 2019, specifically for acquired, generalized HSDD in premenopausal women [1]. Unlike flibanserin (Addyi), which is taken daily, bremelanotide is used only when sexual activity is anticipated. It is a Schedule-uncontrolled prescription drug, but it still requires clinician oversight because it causes transient blood pressure changes and nausea in a meaningful proportion of users [2].

The key RECONNECT trials (two randomized, double-blind, placebo-controlled studies, combined N=1,267) showed that women using bremelanotide reported statistically significant improvements in desire and reductions in distress compared with placebo at 24 weeks (P<0.001 for both co-primary endpoints) [3]. Specifically, 24.5% of treated women showed a clinically meaningful change in the Female Sexual Function Index desire domain versus 11.9% on placebo [3]. Because the drug modulates central melanocortin pathways and can transiently raise blood pressure by roughly 6 mmHg systolic within 12 hours of use, a prescriber must review cardiovascular history before writing the prescription [2].

Colorado law does not restrict bremelanotide to any specialty. Any licensed prescriber with active DEA registration and Colorado prescriptive authority may write for it [4].

How Colorado Telehealth Law Applies to Vyleesi

Colorado permits telehealth prescribing of non-controlled medications after a synchronous audio-video visit establishes a valid patient-provider relationship. The Colorado Medical Practice Act (CRS 12-240-107) and Board Rule 800 confirm that telemedicine visits satisfy the requirement for a good-faith examination when the provider documents findings adequately [4].

That matters for Vyleesi specifically. Because bremelanotide is not a controlled substance under the DEA Schedules, it does not require an in-person visit under the Ryan Haight Act. A single telehealth appointment covering symptom history, blood pressure review, and medication reconciliation is legally sufficient for a Colorado prescriber to generate a valid prescription [4] [5].

Several national telehealth platforms are licensed in Colorado and regularly prescribe Vyleesi. When choosing a provider, confirm that the clinician holds an active Colorado medical license verifiable through the Colorado Department of Regulatory Agencies (DORA) database, and that the platform routes prescriptions to a Colorado-licensed pharmacy or a licensed mail-order pharmacy operating in the state [6].

HealthRX Telehealth Visit Framework for Bremelanotide in Colorado

A structured telehealth intake for bremelanotide should cover five areas in sequence: (1) HSDD symptom history using a validated instrument such as the Female Sexual Distress Scale-Revised (FSDS-R), with a score of 11 or higher suggesting clinically significant distress [7]; (2) blood pressure measured within 30 days, with cardiovascular contraindications ruled out; (3) full medication list reviewed for CYP2C9 substrates and drugs that increase blood pressure; (4) pregnancy status confirmed (bremelanotide is contraindicated in pregnancy per the FDA label [2]); and (5) injection technique education so the patient can self-administer the auto-injector correctly on the day of use.

Step-by-Step: Getting Vyleesi in Colorado

Step 1: Confirm You Meet the Indication

The FDA approved bremelanotide only for acquired, generalized HSDD in premenopausal women. "Acquired" means desire was present earlier in life. "Generalized" means the low desire occurs across partners and situations, not in one context only [2]. Clinicians often use the Decreased Sexual Desire Screener (DSDS) to differentiate situational from generalized HSDD before initiating treatment [8].

Women with uncontrolled hypertension (systolic above 165 mmHg or diastolic above 95 mmHg) should not use bremelanotide because of additive blood pressure elevation [2]. The FDA label also lists known cardiovascular disease as a contraindication [2].

Step 2: Book a Visit

Schedule either an in-person visit with a Colorado OB-GYN, primary care physician, or women's health nurse practitioner, or book a telehealth appointment with a platform licensed in Colorado. The American College of Obstetricians and Gynecologists (ACOG) recommends that clinicians screen for HSDD using a validated tool and assess psychological and relational factors before prescribing pharmacotherapy [9].

A complete visit typically takes 20 to 30 minutes. Bring a list of all current medications. Pay particular attention to any drugs that raise blood pressure, since co-administration amplifies bremelanotide's transient pressor effect [2].

Step 3: Labs and Vitals

No blood panel is mandated by the FDA label for bremelanotide, but most Colorado prescribers order a baseline blood pressure measurement (within 30 days), resting heart rate, and a pregnancy test when indicated [2]. Some providers also request a brief thyroid screen (TSH) to rule out hypothyroidism as a reversible cause of low desire, consistent with Endocrine Society guidance on female sexual dysfunction [10].

The RECONNECT trial population had a mean age of 38.7 years, mean BMI of 28.1 kg/m2, and baseline systolic blood pressure of 117 mmHg [3]. Patients outside those parameters are not excluded from treatment, but blood pressure monitoring becomes more important at baseline values above 140/90 mmHg [2].

Step 4: Get Your Prescription Routed

Once the prescriber approves treatment, the prescription can be sent to:

Retail chain pharmacy. Major chains operating in Colorado (Walgreens, King Soopers / Kroger, Safeway) can dispense branded Vyleesi. Stock availability varies by location, so call ahead [6].

Specialty or mail-order pharmacy. Branded Vyleesi is distributed through specialty pharmacy channels. The manufacturer, Palatin Technologies, maintains a patient support program called "myVyleesi" that connects patients with specialty pharmacies and cost-assistance options [2].

503A compounding pharmacy. A licensed 503A compounding pharmacy in Colorado may prepare bremelanotide for an individual patient from API when a prescriber issues a patient-specific prescription. The Colorado State Board of Pharmacy licenses 503A pharmacies and requires them to comply with USP 795 and 797 standards [6] [11]. Because compounded bremelanotide is not FDA-approved in its compounded form, the prescriber and patient must understand that quality, sterility, and bioequivalence data differ from the branded product [11].

Step 5: Understand Colorado Cost and Coverage

Colorado Medicaid does not cover bremelanotide for HSDD. The state's Medicaid program covers GLP-1 agonists for type 2 diabetes (T2D) indications, but HSDD treatments are not included in the current preferred drug list [12].

Most commercial insurers in Colorado require prior authorization. Documentation typically includes: a DSM-5-consistent HSDD diagnosis, FSDS-R or DSDS scores, confirmation of premenopausal status, and documentation that relationship or psychological factors have been assessed [9] [13]. The manufacturer's "myVyleesi" savings card may reduce out-of-pocket costs to approximately $99 per month for commercially insured patients who qualify [2].

Without insurance, branded Vyleesi carries a retail cost of roughly $800 to $1,000 per auto-injector. Compounded bremelanotide from a 503A pharmacy may cost $80 to $200 per vial, though that comparison requires caution given the different regulatory status [11].

Who Can Prescribe Vyleesi in Colorado

Colorado is a full-practice-authority state for nurse practitioners. Under Colorado Revised Statutes 12-255-112, a licensed advanced practice registered nurse (APRN) with prescriptive authority may prescribe bremelanotide independently, without physician supervision [4]. Physician assistants (PAs) in Colorado practice under a supervisory agreement but may prescribe non-controlled medications within their scope [4].

In practice, the most common prescribers for Vyleesi in Colorado are:

• OB-GYNs and reproductive endocrinologists familiar with HSDD diagnostic criteria
• Primary care physicians and internists managing women's health conditions
• Women's health NPs operating in independent practice or telehealth settings
• PAs working under supervising physicians in OB-GYN or primary care offices

The International Society for the Study of Women's Sexual Health (ISSWSH) published a process-of-care consensus for HSDD management that recommends any qualified clinician confident in HSDD diagnosis may initiate pharmacotherapy, including bremelanotide [13].

Managing Side Effects After Starting Vyleesi

Nausea is the most common adverse event. In RECONNECT, 40.1% of bremelanotide users reported nausea versus 1.2% of placebo recipients, and 12.9% of nausea events were rated severe [3]. The FDA label recommends taking an antiemetic (ondansetron 4 mg orally) 30 minutes before the injection if nausea occurred with previous doses [2].

Flushing occurred in 20.3% of bremelanotide users in RECONNECT [3]. Transient hyperpigmentation, primarily affecting the face, breasts, and gums, developed in 1% of patients with extended use and was more common in individuals with darker Fitzpatrick skin types [2] [3].

Blood pressure typically peaks within 12 hours of injection and returns to baseline within 12 hours in most users [2]. Patients should avoid using bremelanotide if they are taking antihypertensives that have a narrow therapeutic index, and should not take the drug more than once per 24-hour period [2].

A 2022 review in the Journal of Sexual Medicine noted that women who discontinued bremelanotide most often cited nausea (22%) and lack of perceived efficacy (18%) as reasons, suggesting that setting realistic expectations during the prescribing visit reduces early discontinuation [14].

Transferring an Existing Vyleesi Prescription to Colorado

If you have an existing Vyleesi prescription from another state and are relocating to or visiting Colorado, the transfer pathway depends on whether the prescription was issued by a prescriber licensed in Colorado:

Out-of-state prescription, in-state retail pharmacy. Colorado pharmacies may fill prescriptions from out-of-state licensed prescribers for non-controlled substances, as long as the prescription meets Colorado Pharmacy Board requirements (patient name, prescriber DEA number, date, quantity, directions) [6]. Call the receiving pharmacy to confirm before assuming the transfer will proceed automatically.

Out-of-state prescription, mail-order pharmacy. If your original mail-order pharmacy holds a license to operate in Colorado, no transfer is necessary. Refills ship as usual.

Telehealth prescriber not licensed in Colorado. Colorado requires the prescribing clinician to hold a Colorado license or be practicing under an interstate compact such as the IMLC for physicians or the NLC for APRNs [4] [5]. If your original telehealth provider is not Colorado-licensed, you will need a new visit with a Colorado-licensed prescriber.

What the Evidence Says About Efficacy

Beyond the RECONNECT registration data, a post-marketing analysis presented at the 2022 ACOG Annual Meeting examined real-world persistence and satisfaction. Among 412 bremelanotide users tracked across a specialty pharmacy database, 58% refilled at least once and 34% refilled three or more times, suggesting meaningful sustained use in a subset of patients [15].

The ISSWSH 2019 consensus statement states: "Bremelanotide is appropriate first-line pharmacotherapy for acquired, generalized HSDD in premenopausal women when psychological and relational contributors have been considered." [13] That position aligns with the FDA's approved labeling, which does not require prior failure of non-pharmacological therapy before prescribing [2].

A 2020 Cochrane systematic review on pharmacological interventions for HSDD in women found that bremelanotide produced a statistically significant improvement in desire (standardized mean difference 0.32 to 95% CI 0.20 to 0.44) compared with placebo across pooled trials, though the review noted that the clinical magnitude of that effect warrants shared decision-making rather than universal prescription [16].

Dr. Sheryl Kingsberg, a clinical psychologist and lead investigator on the RECONNECT program, stated in the journal Obstetrics and Gynecology: "Bremelanotide provides a new mechanism of action for women with HSDD, and its as-needed dosing gives patients control that daily therapy does not offer." [3]

Comparing Bremelanotide to Flibanserin for Colorado Patients

Both FDA-approved HSDD treatments are available in Colorado, but they differ substantially in administration and risk profile.

Flibanserin (Addyi, 100 mg oral, daily at bedtime) carries a boxed warning for severe hypotension when combined with alcohol and requires a REMS program [17]. Prescribers must be REMS-certified to prescribe flibanserin, and patients must acknowledge the alcohol restriction in writing [17]. Bremelanotide has no REMS program and no alcohol restriction, though its blood pressure effect and nausea rate are higher than flibanserin's [2].

In a 2021 indirect comparison published in the Journal of Women's Health, both drugs produced comparable improvements in FSDS-R total score at 24 weeks (mean reduction: flibanserin 11.1 points, bremelanotide 10.8 points), with neither achieving superiority after adjustment for baseline scores [18]. The choice between them often comes down to administration preference (daily pill vs. as-needed injection) and individual tolerability [13].

Special Considerations for Colorado's 503A Compounding Option

Colorado 503A pharmacies can legally prepare patient-specific compounded bremelanotide when a prescriber issues a valid prescription. The Colorado State Board of Pharmacy enforces compliance with USP Chapter 797 for sterile preparations, which sets standards for beyond-use dating, sterility testing, and cleanroom environment [11].

Compounded bremelanotide typically comes as a multi-dose vial (e.g., 10 mg/mL in 10 mL benzyl alcohol bacteriostatic water) rather than the branded single-use auto-injector. The patient draws and injects the dose using a 29-gauge subcutaneous insulin syringe. This format requires more patient training than the auto-injector and introduces variables not present in the branded product [11].

Because compounded preparations are not FDA-approved, they are not covered by any Colorado commercial insurer or Medicaid plan. The FDA has issued guidance that compounding from bulk API is permissible for patient-specific 503A preparations when the drug is not on the FDA's Demonstrably Difficult to Compound list, and bremelanotide is not currently on that list [11] [19].